Patent Applications Filed on Compounds to Treat Memory Loss
Bionomics Limited (ASX:BNO; ADR:BMICY) today announced the filing of two patent applications covering compounds that are activators of the alpha7 nicotinic acetylcholine receptor.
The prevalence of conditions where an effective, memory-improving drug may find clinical application is large, providing a very significant commercial opportunity. Bionomics' compounds, which have potent activity in restoring memory in animal tests, have the potential to treat Alzheimer's disease by both improving memory and reducing brain tissue inflammation. Activation of the alpha7 nicotinic acetylcholine receptor may also improve function in a variety of neuropsychiatric diseases that feature memory impairment including schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD) as well as in mood and anxiety disorders.
The compounds covered by the patent applications exert their effects only when the natural activator of the receptor, acetylcholine, is present. This approach allows "fine-tuning" of receptor activity with a broader margin of safety, enhancing the normal function of the receptor without unwelcome side-effects.
Dr Andrew Harvey, Bionomics' VP of Drug Discovery, commented "We are very excited to reach this milestone in the alpha7 program. The compound series described in the patents have tremendous potential for further development."
Download this document